First Drug for Postpartum Depression Approved by USFDA

The US Food and Drug Administration (FDA) has approved a drug for the treatment of postpartum depression (PPD) in adult women.

Postpartum depression (PPD) commonly known as "baby blues" is a type of mood disorder associated with childbirth, that affects mainly the new mothers. A new drug to treat PPD in adult women has been recently approved by the US Food and Drug Administration (FDA).//

The FDA on Tuesday approved intravenous infusion of the drug brexanolone, which will be sold as Zulresso. It is the first drug approved by the FDA specifically for PPD, Xinhua quoted a FDA release as saying.

What you need to know about Postpartum Psychosis?
What is Postpartum Psychosis? Find the facts of Puerperal (postpartum) psychosis including symptoms, causes, treatment, diagnosis, stages and more information

‘Postpartum depression affects one in nine mothers; when it turns severe, it becomes life-threatening.’

Zulresso will be administered as a continuous IV infusion over 60 hours, according to the statement.

Patients will be counselled on the risks of the treatment and instructed to be monitored for the side effects at a health care facility for the entire duration of infusion.

PPD is a major depressive episode that occurs following childbirth, although symptoms can start during pregnancy. According to statistics, PPD impacts one in nine new mothers after childbirth.

Postpartum Thyroiditis - Causes, Symptoms, Diagnosis and Treatment
Postpartum thyroiditis is an autoimmune thyroid disorder where the levels of thyroid hormone are abnormal within a year following childbirth.

"Postpartum depression is a serious condition that, when severe, can be life-threatening. It's first time that a drug has been specifically approved to treat postpartum depression, providing an important new treatment option," said Tiffany Farchione from the FDA.

Zulresso will be available to patients only through a restricted distribution program at certified health care facilities. It is likely to be priced $20,000-35,000 per treatment, said Sage Therapeutics, the company that developed the drug.

Brachial Plexus Injury-Causes-Risk factors-Symptoms-Complications-Diagnosis-Treatment
Brachial plexus is a network of nerves that transmits signals from the spine to shoulder, arm and hand.

The medication will be available in June.

Labor-Introduction
Childbirth is one of the most marvelous and memorable segment in a woman's life that calls for celebration. Knowledge about labor and delivery can ease unnecessary fear, ensuring a unique experience.

Source-IANS